Orphan quality control shapes network dynamics and gene expression.
MCRS1
MYC
UBR5
branched ubiquitin chain
orphan quality control
proteasome
stem cell
transcription factor
ubiquitin
Journal
Cell
ISSN: 1097-4172
Titre abrégé: Cell
Pays: United States
ID NLM: 0413066
Informations de publication
Date de publication:
03 08 2023
03 08 2023
Historique:
received:
06
11
2022
revised:
13
04
2023
accepted:
21
06
2023
medline:
7
8
2023
pubmed:
22
7
2023
entrez:
21
7
2023
Statut:
ppublish
Résumé
All eukaryotes require intricate protein networks to translate developmental signals into accurate cell fate decisions. Mutations that disturb interactions between network components often result in disease, but how the composition and dynamics of complex networks are established remains poorly understood. Here, we identify the E3 ligase UBR5 as a signaling hub that helps degrade unpaired subunits of multiple transcriptional regulators that act within a network centered on the c-Myc oncoprotein. Biochemical and structural analyses show that UBR5 binds motifs that only become available upon complex dissociation. By rapidly turning over unpaired transcription factor subunits, UBR5 establishes dynamic interactions between transcriptional regulators that allow cells to effectively execute gene expression while remaining receptive to environmental signals. We conclude that orphan quality control plays an essential role in establishing dynamic protein networks, which may explain the conserved need for protein degradation during transcription and offers opportunities to modulate gene expression in disease.
Identifiants
pubmed: 37478862
pii: S0092-8674(23)00691-8
doi: 10.1016/j.cell.2023.06.015
pii:
doi:
Substances chimiques
Transcription Factors
0
Ubiquitin-Protein Ligases
EC 2.3.2.27
MYC protein, human
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
3460-3475.e23Subventions
Organisme : NCRR NIH HHS
ID : S10 RR025622
Pays : United States
Organisme : Howard Hughes Medical Institute
Pays : United States
Commentaires et corrections
Type : ErratumIn
Informations de copyright
Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests M.R. is a co-founder and an SAB member of Nurix, Zenith, and Lyterian Therapeutics; an SAB member for Monte Rosa and Vicinitas Therapeutics; and an iPartner at The Column Group. N.H.T. receives funding from the Novartis Research Foundation and is an SAB member of Monte Rosa Therapeutics.